Correlation Between Protalix Biotherapeutics and Inozyme Pharma

Can any of the company-specific risk be diversified away by investing in both Protalix Biotherapeutics and Inozyme Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protalix Biotherapeutics and Inozyme Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Protalix Biotherapeutics and Inozyme Pharma, you can compare the effects of market volatilities on Protalix Biotherapeutics and Inozyme Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protalix Biotherapeutics with a short position of Inozyme Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protalix Biotherapeutics and Inozyme Pharma.

Diversification Opportunities for Protalix Biotherapeutics and Inozyme Pharma

-0.91

Correlation Coefficient

Protalix Biotherapeutics  Inozyme Pharma

Pay attention - limited upside

The 3 months correlation between Protalix and Inozyme is -0.91. Overlapping area represents the amount of risk that can be diversified away by holding Protalix Biotherapeutics and Inozyme Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inozyme Pharma and Protalix Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protalix Biotherapeutics are associated (or correlated) with Inozyme Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inozyme Pharma has no effect on the direction of Protalix Biotherapeutics i.e., Protalix Biotherapeutics and Inozyme Pharma go up and down completely randomly.

Pair Corralation between Protalix Biotherapeutics and Inozyme Pharma

Considering the 90-day investment horizon Protalix Biotherapeutics is expected to generate 1.0 times more return on investment than Inozyme Pharma. However, Protalix Biotherapeutics is 1.0 times less risky than Inozyme Pharma. It trades about 0.16 of its potential returns per unit of risk. Inozyme Pharma is currently generating about -0.1 per unit of risk. If you would invest  114.00  in Protalix Biotherapeutics on October 10, 2024 and sell it today you would earn a total of  110.00  from holding Protalix Biotherapeutics or generate 96.49% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Protalix Biotherapeutics  vs.  Inozyme Pharma

Protalix Biotherapeutics

Risk-Adjusted Performance

26 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 26 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Inozyme Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Protalix Biotherapeutics and Inozyme Pharma

The main advantage of trading using opposite Protalix Biotherapeutics and Inozyme Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protalix Biotherapeutics position performs unexpectedly, Inozyme Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inozyme Pharma will offset losses from the drop in Inozyme Pharma's long position.

The idea behind Protalix Biotherapeutics and Inozyme Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.